Agenus (NASDAQ:AGEN) Posts Quarterly Earnings Results, Beats Expectations By $1.83 EPS

Agenus (NASDAQ:AGEN) released its quarterly earnings results on Monday. The biotechnology company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.83, Zacks reports. The firm had revenue of $34.20 million for the quarter, compared to the consensus estimate of $28.10 million.

Agenus Price Performance

NASDAQ AGEN opened at $3.29 on Tuesday. The business’s fifty day moving average is $3.26 and its 200-day moving average is $3.77. The stock has a market capitalization of $111.89 million, a price-to-earnings ratio of -1.54 and a beta of 1.57. Agenus has a one year low of $1.38 and a one year high of $7.34.

Institutional Trading of Agenus

Several hedge funds have recently added to or reduced their stakes in AGEN. Goldman Sachs Group Inc. grew its position in shares of Agenus by 35.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 61,749 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 16,034 shares during the period. Captrust Financial Advisors bought a new stake in shares of Agenus in the 2nd quarter worth approximately $169,000. ExodusPoint Capital Management LP purchased a new position in Agenus in the fourth quarter valued at approximately $149,000. Arrowstreet Capital Limited Partnership purchased a new position in Agenus in the third quarter valued at approximately $120,000. Finally, Virtu Financial LLC bought a new position in Agenus during the fourth quarter valued at $108,000. Institutional investors own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Agenus currently has an average rating of “Hold” and a consensus price target of $14.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.